RE: Kicking off again11 Jun 2025 15:29
Myles McNulty
@MylesMcNulty
·
1h
Recently bought back into biotech micro-cap, Solvonis Therapeutics #SVNS (added more today on the pullback - av. now ~0.15p).
Following its recent all-paper acquisition of Awakn Life Sciences Corp for £5m, the company became a clinical-stage biotech developing novel medicines for addiction and mental health disorders.
Solvonis has two drugs in the clinic. Its lead asset is SVN-001, which commenced a Phase 3 trial in Q3 last year, and which is slated to complete next year or possibly in 2027. A three-way partnership between the company, the UK Department of Health and the University of Exeter ensures that the total cash cost for Solvonis for running this pivotal trial is capped at only £0.8m.
The primary endpoint of the P3 trial is the reduction in heavy drinking days ('HDD') over a six-month period post-treatment.
Now to the key bit of info that really caught my eye:
"A phase 2 trial was successfully completed with efficacy proven, achieving 86% abstinence on average over the 6 months post-treatment versus 2% pre trial and a 50% reduction in HDD versus placebo."
As CEO Anthony Tennyson explains in the video below, prior to entering the programme, patients were sober on average for roughly only 7 days per year. Those who then went through the active arm of the trial, achieved 86% sobriety - or approx. 314 days per year - in the six months post treatment.
Groundbreaking, in Tennyson's own words, and the primary reasons why the UK Department of Health has agree to largely fund the ongoing P3 trial.
At 0.16p, SVNS has a mkt cap of £9.5m. Following the recent equity raise (£2m at 0.13p), it has an enterprise value of
Sign In
Follow the stocks
